SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 316 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $230,540 | -8.3% | 8,362 | 0.0% | 0.02% | -10.7% |
| Q2 2023 | $251,362 | -10.9% | 8,362 | -29.6% | 0.03% | -15.2% |
| Q2 2020 | $282,000 | +36.9% | 11,876 | +91.0% | 0.03% | -10.8% |
| Q2 2019 | $206,000 | -41.0% | 6,217 | -37.5% | 0.04% | -45.6% |
| Q1 2019 | $349,000 | +42.4% | 9,946 | +34.9% | 0.07% | +25.9% |
| Q4 2018 | $245,000 | -17.5% | 7,374 | +48.5% | 0.05% | -14.3% |
| Q2 2018 | $297,000 | -37.3% | 4,966 | -52.0% | 0.06% | -42.7% |
| Q1 2018 | $474,000 | +107.9% | 10,342 | +81.1% | 0.11% | +96.4% |
| Q4 2017 | $228,000 | -18.3% | 5,712 | -11.7% | 0.06% | -13.8% |
| Q2 2017 | $279,000 | -34.7% | 6,470 | -52.5% | 0.06% | -32.3% |
| Q1 2017 | $427,000 | +43.3% | 13,630 | +15.4% | 0.10% | +31.5% |
| Q4 2016 | $298,000 | -23.6% | 11,807 | -25.1% | 0.07% | -18.0% |
| Q3 2016 | $390,000 | +64.6% | 15,756 | +35.2% | 0.09% | +64.8% |
| Q2 2016 | $237,000 | – | 11,657 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |